XVARY Composite Score
40
/ 100
Below Average
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Ars sells neffy, a needle-free epinephrine nasal spray for severe allergic reactions when seconds matter.
How it gets paid
Last year Ars Pharmaceuticals made $84M in revenue.
Why growth slowed
Revenue fell 5.5% last year. $56 million matters most because it is two-thirds of the entire $84 million trailing revenue base.
What just happened
Revenue hit $56M, up 73% vs. prior year, but EPS fell to -$1.32 as spending stayed heavy.
At a Glance
B balance sheet — gets the job done, barely
40/100 earnings predictability — expect surprises
3.1% return on capital — nothing to write home about
-$1.74 fy2025 eps est
$2B fy2026 rev est
XVARY composite: 40/100 — below average
What They Do
Ars sells neffy, a needle-free epinephrine nasal spray for severe allergic reactions when seconds matter.
The pitch is brutally simple: when your throat is closing, a nasal spray is easier than a needle. neffy reached blood levels comparable to approved injectable epinephrine in company studies, and latest-quarter revenue hit $56 million on just $84 million trailing revenue. That speed matters because if patients, parents, and schools trust your product first, you can become the default refill before copycats arrive.
How They Make Money
$84M
annual revenue · revenue declined -5.5% last year
total revenue
$84M
5.5%
The Products That Matter
Needle-free anaphylaxis treatment
neffy
$84.3M revenue · 60% gross margin
it's the entire commercial story today. neffy generated $84.3M in 2025 revenue, and because it is 100% of sales, every launch win or stumble flows straight through the whole company.
only product
Key Numbers
$2.0B
2026 sales view
That forecast is about 24 times trailing revenue of $84 million. Translation: you are buying a ramp, not a mature business.
$96M
debt load
Long-term debt is 10% of capital. Translation: leverage is not the main problem; proving demand is.
5/100
volatility score
A score of 5 out of 100 means the stock has been extremely erratic. So what: your timing matters more here than in a boring drug stock.
n/a
operating margin
Prior margin KPI failed sanity check — verify in filings. Operating margin means profit after running the business. Plain English: Ars loses more than $2 for every $1 of sales, so scale is still theoretical.
Financial Health
B
Strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $96M (10% of capital)
B — functional but not a standout on the balance sheet.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
beat estimates
Revenue hit $56M, up 73% vs. prior year, but EPS fell to -$1.32 as spending stayed heavy.
Sales growth finally showed up in the reported numbers. The problem is the company still posted a much deeper loss, which means commercial traction has not yet turned into durable profitability.
$56M
revenue
$1.32
eps
60.0%
gross margin
the number that mattered
$56 million matters most because it is two-thirds of the entire $84 million trailing revenue base, which says the launch curve just got very steep.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The #1 risk is neffy launch execution on a one-product income statement.
Med
One product, one point of failure
100% of revenue comes from neffy. If demand stalls, safety concerns emerge, or reimbursement disappoints, there is no second asset here to catch the fall.
This risk effectively touches 100% of the current $84.3M revenue base.
Med
Cash burn outrunning commercialization
SPRY posted a $171.3M net loss on $84.3M of revenue, and the operating margin was -63.6%. That is the math of a launch that still costs far more than it returns.
At that run rate, improving gross margin alone will not save the model. Revenue has to scale a lot faster.
Med
Aptar litigation and supplier pressure
The trade-secret case involving Aptar matters because this is not abstract legal noise. Aptar is a key supplier, so a legal fight can bleed into manufacturing, timing, and cost.
For a company with one commercial product, even a narrow supply disruption can hit the whole business.
A slow launch already produced a $171.3M loss on $84.3M of revenue. If neffy adoption does not inflect, the financial pressure is not theoretical.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Commercial
Whether revenue starts matching the spending
The core question is simple: does quarterly revenue move meaningfully above the recent $28.09M Q4 pace while losses narrow from the current -$0.41 EPS level.
Earnings
Q1 2026 earnings report
May 13, 2026 — the next print matters because the market wants launch proof, not another small estimate beat.
Regulatory
Canada neffy decision
Q2 2026 — a positive decision for neffy 2 mg would add another commercialization path. A delay keeps the story US-only for longer.
Legal
Aptar litigation update
Ongoing — because Aptar is a key supplier, legal headlines here matter more than the average biotech lawsuit.
Analyst Rankings
earnings predictability
40 / 100
in human-speak, analysts do not have a clean handle on the near-term numbers. launch-stage biotech estimates break easily.
risk rank
4
that means it is safer than only 20% of stocks in this framework. you should expect volatility, not smooth compounding.
Source: institutional data
Institutional Activity
institutional ownership data for SPRY is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$9
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive